Peptide RX

back to claim graph

proof receipt / target

Klotho-FGF23

α-Klotho / FGF23 axis

grade B status longevity receipt 7d1593abc2e4 proof 33%

what this node claims

Klotho-FGF23

α-Klotho / FGF23 axis

Open source surface

vertical proof spine

  1. 01 Klotho-FGF23 target / grade B / 70% 1 debt
  2. 02 KL WT fold / grade B / 73% 2 debt

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 21%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    single_pass_TM
    functional sites
      gene symbol
      KL
      go terms
        uniprot
        Q9UEF7

        AlphaFold metrics visual

        Confident backbone model

        89.1

        1012 residues / min 28.19 / max 98.81 / source alphafold db

        PAE matrix for linked target
        Very high 72.9% 738 residues / >=90
        Confident 17.5% 177 residues / 70-89
        Low 4.1% 41 residues / 50-69
        Very low 5.5% 56 residues / <50

        usable fold context with explicit model-confidence limits

        Near-complete coverage / observed 1012 of 1012 residues.

        • residues 1-33 / mean 37.0
        • residues 97-119 / mean 41.65
        • residues 957-979 / mean 56.7
        • residues 1007-1012 / mean 55.1
        proof debt register

        Visible limits, not hidden cleanup.

        21%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:b54b3084-fa26-423d-b8ed-1dc4d20b39f1 -> fold:eeefd326-126b-483a-8a74-9bf047523bf7 folds_to / B / 0.891

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.